Answers are grounded in this paper and cite their sources.
Guanylin (GUCA2A) and uroguanylin (GUCA2B) are paracrine hormone ligands of the tumor-suppressor receptor guanylyl cyclase C (GUCY2C). In early colorectal tumorigenesis, expression of GUCA2A and GUCA2B is silenced through transcriptional repression by APC-regulated β-catenin/TCF signaling, a pathway activated early in malignant transformation. This repression depends on a locus control region (LCR) 1,000-3,683 bp upstream of GUCA2A. Here, we used dCas9-APEX2 biotinylation at genomic elements by restricted spatial tagging (C-BERST) in colorectal cancer (CRC) cell lines with inducible suppression of β-catenin/TCF signaling to identify β-catenin/TCF-regulated proteins associated with the GUCA2A regulatory region that mediate repression of GUCY2C ligand transcription. Guide RNAs were used to direct dCas9-APEX2 for locus-specific proximity biotinylation of proteins. Quantitative mass spectrometry identified p38α (MAPK14) as a candidate regulator enriched near the GUCA2A promoter following β-catenin/TCF suppression. Loss-of-function and rescue experiments established that p38α supports GUCA2A and GUCA2B induction following β-catenin/TCF suppression. Importantly, GATA2 was identified as a p38α-dependent activator of GUCA2A and GUCA2B transcription that remained enriched near the GUCA2A promoter independent of β-catenin/TCF signaling. Indeed, GATA2 S192 phosphorylation was reduced by p38α loss and by active β-catenin/TCF signaling. Thus, a p38α/GATA2 axis links oncogenic β-catenin/TCF signaling to repression of GUCY2C hormone expression in CRC.
No takes yet. Share an insight, caveat, or question.
Caspi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: